Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors
Single-center Real World Prospective Observational Study of Clinical Features, Treatment Patterns, and Survival of Bone and Soft Tissue Tumors
1 other identifier
observational
6,000
1 country
1
Brief Summary
It is planned to prospectively collect, collate and report real-world clinical data of BSTS patients treated in our hospital in the next ten years to evaluate the changes in clinical characteristics, treatment patterns and survival information of these patients, in order to provide reference for clinical treatment and research of this type of tumor.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 19, 2022
CompletedFirst Posted
Study publicly available on registry
July 21, 2022
CompletedStudy Start
First participant enrolled
August 3, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2032
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 31, 2032
September 1, 2023
August 1, 2023
10 years
July 19, 2022
August 31, 2023
Conditions
Outcome Measures
Primary Outcomes (2)
Overall survival
Pathologically confirmed events leading to death
Up to approximately 120months
6/5000 Progression-free survival
The time from the first use of the treatment to the observation of disease progression
Up to approximately 48months
Interventions
NO Intervention
Eligibility Criteria
Patients with bone and soft tissue tumors receiving inpatient treatment in Henan Tumor Hospital.
You may qualify if:
- All ages, male and female.
- The pathological diagnosis of BSTS in our hospital was a subtype.
- Has received at least one hospitalization in this hospital.
- The target lesions could be evaluated according to the efficacy evaluation criteria of solid tumor (RECIST; Version 1.1) Measure diameter changes.
You may not qualify if:
- No definite pathology.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Bone and Soft Tissue ,Henan Cancer Hospital
Zhengzhou, Henan, 450008, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate chief physician
Study Record Dates
First Submitted
July 19, 2022
First Posted
July 21, 2022
Study Start
August 3, 2022
Primary Completion (Estimated)
July 31, 2032
Study Completion (Estimated)
July 31, 2032
Last Updated
September 1, 2023
Record last verified: 2023-08